Is LENSAR Inc (LNSR) a Buy, Sell, or Hold?
LENSAR Inc
NASDAQ:LNSR
$5.76 USD
-$0.06 (-1.03%)
- Volume
- 32.87K
- Average Volume
- 81.74K
- Market Capitalization
- $69.72M
- P/E Ratio
- 5.88
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $13.43
- Year Low
- $5.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.38
| Source | Headline |
|---|---|
|
LENSAR Q1 Earnings Call Highlights
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes. marketbeat.com - 2026-05-08 16:04:15 |
|
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-08 11:31:25 |
|
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 globenewswire.com - 2026-05-08 07:00:00 |
|
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. globenewswire.com - 2026-04-30 07:00:00 |
|
Head-To-Head Review: LENSAR (NASDAQ:LNSR) vs. Edwards Lifesciences (NYSE:EW)
LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99, defenseworld.net - 2026-04-27 01:44:44 |
